
Orthofix Medical Inc. Launches OsteoCove™ Synthetic Bone Graft
Orthofix Medical Inc. (NASDAQ: OFIX), a spine and orthopedics company, has announced the launch of OsteoCove™, a new bioactive synthetic graft which recently obtained 510k clearance from the FDA. Synthetic bone graft refers to artificially produced materials that are used to augment or extend the availability of autograft bone, which is bone harvested from the patient’s own body. There are various types of extender biomaterials and tissues in the market, and their properties are influenced by their source and processing methods. Synthetic bone graft operates through a process known as osteoconduction. This process provides a support matrix for new bone growth, and in the case of synthetic bone graft, it serves as a scaffold that provides support for bone-forming cells as they gradually generate new bone over time. This method facilitates bone growth and repair within the patient’s body. The U.S. synthetic bone graft market is estimated to be valued at $300 million per year.
OsteoCove™ is available in both putty and strip configurations, OsteoCove is designed to provide bone-forming capabilities for orthopedic and spinal surgeries. OsteoCove consists of biphasic ceramic granules, composed of β-tricalcium phosphate (ß-TCP) and hydroxyapatite (HA), blended with type-I bovine collagen. What sets OsteoCove apart is its unique granule surface topography, designed to induce a bone-forming response.
Tyler Lipschultz, President of Orthofix Global Biologics, commented, “Orthofix is a leader in both the demineralized bone matrices (DBM) and cellular allograft markets, and the launch of OsteoCove significantly strengthens our biologics portfolio and builds on our mission to deliver best-in-class products in every major bone grafting category. With the introduction of OsteoCove, we expect strong growth in this large market segment as we continue to deliver on our commitment to provide surgeons a comprehensive offering of biologic solutions to meet the needs of their patients.”